Ticker Details
Biogen Inc. Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
IPO Date:	January 3, 1994
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$28.18B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$2.46 | 1.33%
Avg Daily Range (30 D):	$3.20 | 1.76%
Avg Daily Range (90 D):	$2.45 | 1.43%

Institutional Daily Volume
Avg Daily Volume:	2.07M
Avg Daily Volume (30 D):	1.19M
Avg Daily Volume (90 D):	1.41M

Trade Size
Avg Trade Size (Sh.):	105
Avg Trade Size (Sh.) (30 D):	39
Avg Trade Size (Sh.) (90 D):	43

Institutional Trades
Total Institutional Trades:	44,687
Avg Institutional Trade:	$6.16M
Avg Institutional Trade (30 D):	$13.96M
Avg Institutional Trade (90 D):	$16.31M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	7

Market Closing Trades
Avg Closing Trade:	$28.38M
Avg Closing Trade (30 D):	$46.64M
Avg Closing Trade (90 D):	$55.43M
Avg Closing Volume:	138.56K

News

Feb 19, 2026 @ 8:30 AM Global Amyotrophic Lateral Sclerosis Therapeutics ... Source: Custom Market Insights

Feb 18, 2026 @ 12:00 PM Alzheimer's Therapeutics Market Research Report 20... Source: Researchandmarkets.Com

Feb 11, 2026 @ 10:00 PM Biogen Announces Board Chair Transition Source: Na

Feb 6, 2026 @ 4:20 PM Philip Morris Beats Estimates as Smoke-Free Produc... Source: Timothy Fries

Feb 6, 2026 @ 3:33 PM Biogen Hits 52-Week High, Alzheimer's Drug Sales J... Source: Vandana Singh

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$8.83	$-.33	$8.83
Diluted EPS	$8.79	$-.35	$8.79
Revenue	$9.89B	$2.28B	$9.89B
Gross Profit	$7.49B	$1.78B	$7.49B
Net Income / Loss	$1.29B	$-48.9M	$1.29B
Operating Income / Loss	$1.56B	$-56M	$1.56B
Cost of Revenue	$2.4B	$495.5M	$2.4B
Net Cash Flow	$633.5M	$-854.3M	$633.5M
PE Ratio	22.14

Splits
Jan 18, 2001	3:1